Update on GSK's response to the novel coronavirus (COVID-19): your questions answered

You may be eligible for our dollars-off coupons if you're commercially insured, such as having health insurance through your employer. Restrictions apply. For more information, and to view the dollars-off coupons currently available, click on the appropriate medicine below:

ANORO ELLIPTA TRELEGY ELLIPTA

Note: If you're eligible for a dollars-off coupon, you'll be temporarily allowed to use it on prescription refills that are picked up early, to make sure you have enough medicine on hand.

Co-pay programs are available for eligible patients with commercial insurance. For eligibility, click on the appropriate medicine below:

BENLYSTA NUCALA

Get information about other resources, including patient assistance programs and reimbursement support for our other products.

For decades, we have helped patients who need financial assistance with access to our medicines and vaccines. Our commitment to help patients in this time of need continues.

GSK Patient Assistance programs for patients in the U.S., Puerto Rico, and U.S. Virgin Islands provide some medicines and vaccines at no cost to patients who meet program eligibility criteria.

To see if you're eligible, click the appropriate link below:

Oncology products BENLYSTA or NUCALA Other GSK prescription medicines

Please talk to your healthcare provider. Unless your healthcare provider recommends a change, you should continue to receive your GSK vaccinations as prescribed.

If you have questions around getting your next dose, please contact the GSK Response Center at 1-888-825-5249.

Right now, we're making our medicines, vaccines, and consumer healthcare products as usual. We're focused on managing our global supply chains to support patients and consumers who depend on our products.

We've taken a number of measures to support supply of our products, including increasing manufacturing to produce some high demand respiratory products around the clock, using the fastest methods available to transport products from our facilities, and actively managing supply.

If, for some reason, your pharmacy doesn't have your medication in stock, consider checking with other pharmacies or ask your doctor about mail-order pharmacy options.

If you have a question about GSK products, vaccines, product availability, and/or need to report potential product side effects, please contact the GSK Response Center at 1-888-825-5249.

Taking care of your health is the most important thing right now. This means continuing to take any medication as prescribed by your healthcare provider. If you have questions about your medications or your risk of COVID-19, please contact your healthcare provider.

If you have a question about GSK products, vaccines, product availability, and/or need to report potential product side effects, please contact the GSK Response Center at 1-888-825-5249.

Your treatment may have other administration options available. Speak with your healthcare provider to determine which option is best for you during this time.

You can also contact the GSK Response Center at 1-888-825-5249 for more information.

As the world's largest vaccines maker, we're working with companies and research groups across the world on promising COVID-19 vaccine candidates through the use of our innovative vaccine adjuvant technology. The use of an adjuvant is of particular importance in a pandemic situation since it may reduce the amount of vaccine protein required per dose, allowing more vaccine doses to be produced and therefore contributing to protecting more people. We have committed to produce 1 billion doses.

We recently announced that GSK joined forces with Sanofi, bringing together two of the world's largest vaccines companies in collaboration to fight COVID-19. The two companies expect a candidate vaccine to enter clinical trials in the second half of 2020 and, if successful and subject to regulatory considerations, aim to complete the development required for availability by the second half of 2021.

In addition, the GSK and Sanofi partnership was selected for Operation Warp Speed to supply the United States government with 100 million doses of COVID-19 vaccine.

To learn more about our actions to support the global response to COVID-19, visit our COVID-19 Resource Center.

GSK is using our science, technology, and portfolio to support development of products for prevention/treatment of COVID-19. As the world's largest vaccines maker, we're also working with key partners to identify ways of preventing the virus.

Hear from our CEO, Emma Walmsley as she discusses GSK's response to COVID-19 including our collaboration with Sanofi to develop an adjuvanted COVID-19 vaccine, our commitment to access and investment in long-term pandemic preparedness. We have committed to produce 1 billion doses.

GSK is also donating $10 million to The COVID-19 Solidarity Response Fund, created by the UN Foundation and WHO. The Fund will support the WHO and it's partners in their efforts to prevent, detect, and manage the pandemic, particularly where the needs are greatest.

GSK has also started new volunteering processes for people working at the company, to allow those with medical expertise to provide support to frontline health workers. In addition, our salesforce personnel have started to help with delivery of PPE and testing equipment, and our specialists, such as procurement leaders, are working with national governments on developing supply chains.

To learn more about our actions to support the global response to COVID-19, visit our COVID-19 Resource Center.

If you have a question about GSK products, vaccines, product availability, and/or need to report potential product side effects, please contact the GSK Response Center at 1-888-825-5249.

If you have a question or concern about the impact of COVID-19 on your health, your prescription medicines, or your vaccines, please contact your healthcare provider. They will have the appropriate information for your specific situation and needs.

If you're not sure if your prescription medication is a GSK product, you can search for it here.

Questions last updated on 8/25/2020

Message from Maya Martinez-Davis
President, U.S. Pharmaceuticals

As the coronavirus (COVID-19) continues to affect communities in the U.S. and globally, our hearts go out to those impacted. While the pandemic situation evolves, GSK remains committed to contributing to the fight against COVID-19 and protecting and supporting our people, as well as our, patients, customers, and partners.

Over the past several weeks, we have mobilized across the company to respond to the pandemic, focusing on our people, and providing solutions to support the global response. We're continuing to actively explore ways to help with our science and expertise and manage our global supply chains to support those who depend on our products. Informed by science and in partnership with health authorities, we're taking the following steps to protect your health and well-being and that of our employees and our communities.

Helping patients with financial assistance.

For decades, we've helped patients who need financial assistance with access to our medicines and vaccines. Our commitment to help patients in this time of need continues.

GSKForYou offers patients and healthcare professionals specific resources that may help them, including charitable products, patient assistance programs, coupon and co-pay programs and reimbursement support.

Ensuring medicine supply and access.

We're focused on managing our global supply chains to support patients and consumers who depend on our products.

We've taken a number of measures to support supply of our products, including increasing manufacturing to produce some high demand respiratory products around the clock, using the fastest methods available to transport products from our facilities, and actively managing supply.

Contributing to the fight against COVID-19.

GSK is harnessing science, technology and our portfolio to support development of medicine and vaccines for the prevention and treatment of COVID-19.

As the world's largest vaccines maker, we're working with companies and research groups across the world on promising COVID-19 vaccine candidates through the use of our innovative vaccine adjuvant technology. The use of an adjuvant is of particular importance in a pandemic since it may reduce the amount of vaccine protein required per dose, allowing more vaccine doses to be produced. We have committed to produce 1 billion doses.

We recently announced that GSK joined forces with Sanofi, bringing together two of the world's largest vaccine companies in collaboration to fight COVID-19. We expect a vaccine candidate to enter clinical trials in the second half of 2020 and, if successful and subject to regulatory considerations, aim to complete the development required for availability by the second half of 2021.

In addition, the GSK and Sanofi partnership was selected for Operation Warp Speed to supply the United States government with 100 million doses of COVID-19 vaccine.

GSK is also donating $10 million to The COVID-19 Solidarity Response Fund, created by the UN Foundation and the World Health Organization (WHO), to support WHO and partners to prevent, detect, and manage the pandemic, particularly where the needs are the greatest.

Visit our COVID-19 Resource Center to learn more about our actions to support the global response to COVID-19.

Ready to help.

If you have a question or concern about GSK products, vaccines, product availability, and/or need to report potential product side effects, please contact the GSK Response Center at 1-888-825-5249.

If you have a question or concern about the impact of COVID-19 on your health, your prescription medicines, or your vaccines, please call your healthcare provider. They will have the appropriate information for your specific situation and needs.

If you're not sure if your prescription medication is a GSK product, you can search for it here.

Our mission continues to be to support and keep our customers, healthcare workers, and employees safe during this time. Stay safe and healthy.

Sincerely,

Maya Martinez-Davis
President, U.S. Pharmaceuticals

Message last updated: Aug 25, 2020

Please bookmark this page and check back for updates as new information becomes available.